



2017 DTRF Desmoid Tumor Research Workshop

Sunday, September 24, 2017

(Tentative agenda as of 8.10.17)

- 7:15-8:00 Continental breakfast and informal introductions.
- 8:00-8:05 Welcome: **Jeanne Whiting**, President & Co-Founder, DTRF.
- 8:05-8:20 **David Kirsch, MD, PhD**, Barbara Levine University Professor and Vice Chair for Basic & Translational Research, Department of Radiation Oncology Professor, Department of Pharmacology & Cancer Biology, Duke University, *"Using radiation therapy to treat desmoid tumors."*
- 8:20-8:35 **Tom van Cann, MD**, Medical oncologist, KU Leuven, *"Systemic treatment preferences for patients with advanced desmoid-type fibromatosis in Europe."*
- 8:35-8:50 **Yuhong Zhou, MD, PhD**, Professor & Oncologist, Zhongshan Hospital, Fudan University, *"The treatments and clinical outcomes of sporadic and fap-associated desmoid tumor: a single centre long-term observational study."*
- 8:50-9:05 **Milea J.M. Timbergen, MD, PhD candidate**, Erasmus Medical Center, *"Results of the interim analysis of the Dutch GRAFITI study."*
- 9:05-9:20 **Breelyn Wilky, MD**, Assistant Professor in Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, *"Mutation phenotypes and their responses to chemotherapy."*
- 9:20-9:35 *Discussion*
- 9:35- 9:50 **Chiara Colombo MD**, Surgical Oncology, Fondazione IRCCS- Istituto Tumori di Milano, *" β -catenin in Desmoid-Type Fibromatosis: deep insights on the role of T41A and S45F mutations on protein structure and gene expression."*
- 9:50-10:05 **Yoshihiro Nishida, MD, PhD**, Associate Professor, Nagoya University Graduate School of Medicine, *"Effects of mechanical forces on the cell behavior of desmoid-type fibromatosis."*
- 10:05-10:20 **Danielle Braggio, PhD, Post-Doctoral Researcher**, Ohio State University, *"Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors."*
- 10:20- 10:35 **Kris Vleminckx, PhD**, Professor, Department of Molecular Biomedical Research Unit of developmental Biology VIB, Ghent University, *"Therapeutic target identification in a Xenopus model for desmoid tumor formation – an update."*
- 10:35- 10:50 **Gerlinde Wernig, MD**, Assistant Professor of Pathology, Stanford University, *"Unifying mechanism on different fibrotic diseases."*
- 10:50- 11:05 *Discussion*
- 11:05- 11:40 **TBD**
- 11:40- 11:45 **Steve Horrigan, PhD**, Chief Scientific Officer, Beta Cat Pharmaceuticals, *"Tegavivint (BC2059) – A new way of attacking beta catenin driven disease."*
- 11:45- 11:55 **Danielle Braggio, PhD**, Post-Doctoral Researcher in Sarcomas, Ohio State University, *"Tegavivint (BC2059) studies in desmoid cell lines."*

- 11:55- 12:05 **Benjamin Alman, MD**, Professor and Chair, Department of Orthopaedic Surgery, Duke University, *“Tegavivint (BC2059) studies in Apc(+)/Apc(1638N) genetic mouse model of aggressive fibromatosis.”*
- 12:05- 12:15 **Casey Cunningham, MD**, Chief Medical Officer, Beta Cat Pharmaceuticals, *“Synopsis of a Planned Phase 1/2 Study of Tegavivint (BC2059) in Desmoid Tumors.”*
- 12:15- 12:45 *Lunch break- continue discussion*
- 12:45- 1:45 *Lunch*
- 1:45- 2:10 **Benjamin Alman, MD**, Department Chair, Orthopedic Surgery, Duke University, *“Introduction and report on Collaboration for a Cure project.”*
- 2:10- 2:25 **Kelly Mercier, PhD**, RTI International, *“A Metabolomics Pilot Study on Desmoid Tumors and Novel Drug Candidates.”*
- 2:25-2:40 **Aaron Weiss, DO**, Maine Medical Center, *“Development of a DTRF-Sponsored Virtual Tumor Board.”*
- 2:40- 2:50 **Kelly Mercier, PhD**, RTI International, *“DTRF Natural History Study and Patient Registry Launch and Update.”*
- 2:50-4:00 SUMMARY DISCUSSION and SETTING OF PRIORITIES